Abstract: A gas-phase mixture of propene and oxygen is catalytically oxidized by passing a reactant gas mixture comprising propene and oxygen through a plurality of catalyst containing contact tubes in a fixed bed reactor and simultaneously passing only one heat-exchange medium at elevated temperature over the exterior surfaces of the contact tubes in a longitudinal flow pattern which is cocurrent with the direction of flow of the reactants through said tube; simultaneously superposing a transverse flow on said longitudinal flow of heat exchange medium by means of an arrangement of successive baffles along the contact tubes which leave passage cross-sections free, thereby resulting in a meandrous flow of the heat-exchange medium through the reactor and setting the flow rate of said heat-exchange medium so that its temperature between the point of entry of the medium into the reactor and its point of exit increases by 2.degree. to 10.degree. C.; and obtaining product acrolein at a selectivity .gtoreq.

Abstract: As replacements for chlorofluorcarbons, hydro(chloro)fluorocarbons are synthesized by hydrogenating chlorofluorocarbons over a Pd/ZnO/.gamma.--Al.sub.2 O3 catalyst. The ZnO is partially reduced before use and assists the Pd to function catalytically for days instead of hours despite the evolution of halogen.

Abstract: The present invention relates to compounds of formula (I), wherein n is zero, 1, 2 or 3; R represents C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halogen, cyano, trifluoromethyl SO.sub.2 C.sub.1-6 alkyl, NR.sup.a R.sup.b, NR.sup.a COR.sup.b or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are each H, C.sub.1-4 alkyl, phenyl or trifluoromethyl; R.sup.1 represents phenyl optionally substituted by 1, 2 or 3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, --O(CH.sub.2).sub.p O-- (where p is 1 or 2), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, COR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b ; naphthyl; benzhydryl; or benyl, where the naphthyl group or each phenyl moiety of benzyl and benzhydryl may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or trifluoromethyl; R.sup.

Abstract: New 3-arylpyrrolidine-2,4-dione derivatives of the formula (I): ##STR1## in which the variables A, B, E, R, X, Y, Z and n are set forth in the specification, are useful as insecticides, acaricides, and herbicides.

Abstract: The present invention concerns a process for preparing a highly pure adduct of one or more alkylene oxide(s) to a compound which is sufficiently reactive for an addition reaction, said process being carried out in a reaction system designed as a loop-type reactor and comprising the steps of (a) feeding a compound sufficiently reactive for the addition reaction to the reaction system and circulating said compound in the whole system; (b) deaerating the whole reaction system and injecting an inert gas; (c) adding said alkylene oxide(s) with mixing, said addition step taking place at a point of the reaction system which is upstream a heat exchanger which is assembled in the loop and serves as a means for heating; (d) quickly heating a partial amount of the reaction mixture containing freshly admixed alkylene oxide(s) to a temperature allowing a substantial degree of conversion of the reactants; (e) immediately cooling, after reaching said substantial degree of conversion of said reactants, said partial amount of

Abstract: A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.

Abstract: Intercalator compounds are provided which are comprised of intercalator moieties, or substituted intercalator moieties, having one or more functionalized chains, or moieties, and which compounds provide a high affinity for binding to the DNA molecule and show reduced self-quenching, while providing superior transport kinetics. The compounds have been found to provide enhanced fluorescence when bound to a DNA molecule within a fluorescent flow cytometry environment which is about eight to ten times brighter in fluorescence than "bis" structure conventional intercalating agents and other known intercalating agents utilized in flow cytometry environment.

Abstract: A process which can be used to produce an aromatic sulfide compound having the formula of (R.sub.4-n)(X.sub.n)(W)Ar--S--R' is provided. The process comprises contacting, in the presence of a surfactant, a halo-substituted aromatic compound in an aqueous solution with a salt of a mercaptan under conditions sufficient to produce the aromatic sulfide in which the halo-substituted aromatic compound and salt of mercaptan are each present in an amount effective to synthesize the aromatic sulfide wherein R is hydrogen or a hydrocarbyl radical, X is a halogen, n is a number from 0 to 3, W is a substituent, Ar is an aromatic ring, and R' is a hydrocarbyl radical.

Abstract: Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties.

Abstract: The present invention is based upon the surprising discovery that NAALADase inhibitors exhibit a significant inhibitory effect on the growth of prostate cancer cells. The present disclosure relates to methods of treating diseases of the prostate, in particular prostate cancer, using novel compositions which inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in humans and warm-blooded animals. Furthermore, as NAALADase has been found in other tissues of the body it may serve as a cancer associated protein and thus NAALADase inhibitors would be expected to show efficacy in the treatment of other forms of cancer.

Abstract: Disclosed are degradable materials including molded products, laminates, foams, nonwoven materials, adhesives, coatings and films, and particularly packaging films. The materials are made using polydioxaneone polymers comprising at least two different dioxaneone-based repeating units. Preferred polymers are polydioxanediones. First repeating units have less carbon atoms in constituent groups extending from the polymer backbone than second repeating units. Physical characteristics and degradation of the materials can be varied by varying the choice and/or relative proportions of first and second repeating units in the polydioxaneone polymers. Methods for preparing polydioxaneone polymers that can be used in the manufacture of the materials are also discussed, as are suitable monomers and methods for preparing such monomers.

Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia, and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment or prevention a substituted or unsubstituted pyridine and pyridine (N-oxide) analogs of 4-hydroxydihydroquinolones, tetrahydroquinoline-trione-oximes and quinoxalones, tautomers and pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

Abstract: The present invention is directed to recording materials characterized in that the recording materials comprise at least one of diphenyl sulfone derivatives represented by the following general formula (I); ##STR1## wherein Y represents a linear or branched (un)-saturated C.sub.1 -C.sub.12 hydrocarbon group, a C.sub.1 -C.sub.8 hydrocarbon group having an ether linkage, or a group represented by a general formula; ##STR2## wherein R represents methylene or ethylene; R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each independently lower alkyl or lower alkenyl; m represents 0 or an integer of 1 or 2,; and n, p, q and r represent each independently 0 or an integer of 1 to 4, provided when n, p, q and r are each 2 or above, the substituents represented by R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be each different from one another.

Abstract: This invention relates to an ethylene oxide catalyst which contains silver and one or more alkali metal promoters supported on a carrier prepared by a process comprising the use of ceramic particle components with particle sizes chosen to ensure that a desired degree of porosity is obtained without the use of organic burnout materials.

Abstract: This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

Abstract: The compound of the formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, are described. These compounds are antibacterial agents.

Abstract: An antidotal food product containing activated charcoal is provided for ingestion into the gastro-intestinal tract of a user. The antidotal food product is orally administered having the visual appearance and physical properties which enables the desire on the part of young children to chew and ingest the food product. The food product in a preferred embodiment includes a substantially dry friable wafer which is adapted to be chewed by the user for ingestion. The dry friable wafer has a wafer mixture composition formed by blending a first predetermined weight of sorbent particulate composition having an initial adsorption value with respect to a toxin to a second predetermined weight of a substantially non-interfering flavored binding composition which provides for a creamy and sweet tasting food product.

Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d)--NR.sup.6 SO.sub.2 R.sup.

Abstract: The present invention provides a family of tropane analogs. More particularly, the present invention provides a family of 4' and 4',4"-substituted-3.alpha.-(diphenylmethoxy)tropane analogs having the formula ##STR1## in which R is a functional group including, but not limited to, hydrogen, alkyl, alkoxy, arylalkyl, aryloxyalkyl, cinnamyl and acyl; and R.sup.1 and R.sup.2 are independently selected and are functional groups including, but not limited to, hydrogen, alkyl, alkoxy, hydroxy, halogen, cyano, amino and nitro. The benztropine analogs of the present invention have a high affinity for the dopamine transporter and inhibit dopamine uptake, but they do not exhibit a cocaine-like behavioral profile. Moreover, the present invention provides methods of using such benztropine analogs to treat cocaine abuse, to image dopamine transporter/cocaine binding sites, and to diagnose and/or monitor neurodegenerative disorders (e.g., Parkinson's disease).

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 --R.sup.4, R.sup.7 --R.sup.8, R.sup.a, R.sup.b, R.sup.c, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.